US 12,351,633 B2
PD-1 and PD-L1 binding agents
Nikolai Kley, Newton, MA (US); Jan Tavernier, Balegem (BE); Lennart Zabeau, Zwijnaarde (BE); and Erik Depla, Zwijnaarde (BE)
Assigned to Orionis Biosciences, Inc., Waltham, MA (US); and Orionis Biosciences BV, Ghent (BE)
Filed by Orionis Biosciences Inc., Waltham, MA (US); and Orionis Biosciences BV, Ghent (BE)
Filed on Oct. 5, 2022, as Appl. No. 17/938,109.
Application 17/938,109 is a continuation of application No. 16/636,501, granted, now 11,498,966, previously published as PCT/US2018/045743, filed on Aug. 8, 2018.
Claims priority of provisional application 62/542,921, filed on Aug. 9, 2017.
Prior Publication US 2023/0295304 A1, Sep. 21, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/56 (2006.01); C07K 14/565 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); C07K 14/56 (2013.01); C07K 14/565 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01)] 16 Claims
 
1. A PD-1 binding agent comprising at least one targeting moiety comprising three complementarity determining regions (CDR1, CDR2, and CDR3), wherein:
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 2, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 24; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 55;
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 3, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 24; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 56;
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 4, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 25; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 57;
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 5, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 26; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 58;
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 6, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 27; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 59;
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 7, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 27; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 59;
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 8, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 28; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 60;
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 9, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 29; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 61; or
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 10, (b) CDR2 comprises the amino acid sequence of SEQ ID NO: 30; and (c) CDR3 comprises the amino acid sequence of SEQ ID NO: 62.